On May 2, 2022 Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, reported that on April 29, 2022 it completed the previously announced acquisition of Héra SAS ("HRA") for €1.8 billion, or approximately $1.9 billion based on current exchange rates, in cash, accelerating its position as a leading global consumer self-care company (Press release, Perrigo Company, MAY 2, 2022, View Source [SID1234613309]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Perrigo President and CEO, Murray S. Kessler commented, "We are excited to close this acquisition and welcome the talented HRA team to the Perrigo family. Completing this transaction marks the culmination of our three-year transformation plan that has returned Perrigo to its self-care roots. The addition of HRA advances Perrigo’s vision of making lives better with quality affordable self-care products that consumers trust everywhere they are sold. It also accelerates our sales and earnings growth and is expected to enhance our margins. Our global businesses are now more intertwined and unified than ever before as we focus on expanding our geographic reach, driving category penetration and delivering new product innovation that leverages our consumer-centric mindset."